DK3295942T3 - Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion - Google Patents

Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion Download PDF

Info

Publication number: DK3295942T3
Authority: DK; Denmark
Prior art keywords: prophylaxy; pyrimidin; phenoxy; comprehensive; derivatives
Prior art date: 2012-10-08

Application number

DK17191307.2T

Other languages

English (en)

Inventor

Kenneth L Arrington

Christopher Burgey

Robert Gilfillan

Yongxin Han

Mehul Patel

Chun Sing Li

Yaozong Li

Yunfu Luo

Jiayi Xu

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-08

Filing date

2013-10-07

Publication date

2020-02-10

2013-10-07 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2020-02-10 Application granted granted Critical

2020-02-10 Publication of DK3295942T3 publication Critical patent/DK3295942T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Enzymes And Modification Thereof (AREA)

DK17191307.2T 2012-10-08 2013-10-07 Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion DK3295942T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN2012001358		2012-10-08
EP13776702.6A EP2903977B1 (en)	2012-10-08	2013-10-07	5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number	Publication Date
DK3295942T3 true DK3295942T3 (da)	2020-02-10

Family

ID=49354986

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK19210167.3T DK3656384T3 (da)	2012-10-08	2013-10-07	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK17191307.2T DK3295942T3 (da)	2012-10-08	2013-10-07	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK13776702.6T DK2903977T3 (da)	2012-10-08	2013-10-07	5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf som hiv- reverse-transkriptasehæmmere

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK19210167.3T DK3656384T3 (da)	2012-10-08	2013-10-07	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK13776702.6T DK2903977T3 (da)	2012-10-08	2013-10-07	5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf som hiv- reverse-transkriptasehæmmere

Country Status (47)

Country	Link
US (3)	US9469634B2 (da)
EP (3)	EP3295942B1 (da)
JP (2)	JP5877281B2 (da)
KR (1)	KR101696128B1 (da)
CN (1)	CN104822670B (da)
AP (1)	AP2015008355A0 (da)
AR (1)	AR092876A1 (da)
AU (1)	AU2013329552B8 (da)
BR (1)	BR112015007742B8 (da)
CA (1)	CA2887312C (da)
CL (1)	CL2015000880A1 (da)
CO (1)	CO7350655A2 (da)
CR (1)	CR20150183A (da)
CY (3)	CY1119655T1 (da)
DK (3)	DK3656384T3 (da)
DO (1)	DOP2015000082A (da)
EA (1)	EA033436B1 (da)
EC (1)	ECSP15018618A (da)
ES (3)	ES2770774T3 (da)
GE (1)	GEP20186838B (da)
GT (1)	GT201500088A (da)
HK (2)	HK1207369A1 (da)
HR (3)	HRP20220502T1 (da)
HU (3)	HUE037231T2 (da)
IL (1)	IL238090B (da)
JO (1)	JO3470B1 (da)
LT (3)	LT3656384T (da)
MA (1)	MA37959A2 (da)
MD (1)	MD4625C1 (da)
ME (1)	ME02918B (da)
MX (1)	MX355040B (da)
MY (1)	MY192716A (da)
NI (1)	NI201500048A (da)
NO (1)	NO2903977T3 (da)
NZ (1)	NZ706729A (da)
PE (1)	PE20151787A1 (da)
PH (1)	PH12015500764A1 (da)
PL (3)	PL2903977T3 (da)
PT (3)	PT3295942T (da)
RS (3)	RS63112B1 (da)
SG (1)	SG11201502620UA (da)
SI (3)	SI3656384T1 (da)
TN (1)	TN2015000106A1 (da)
TW (2)	TWI598343B (da)
UA (1)	UA114006C2 (da)
WO (1)	WO2014058747A1 (da)
ZA (1)	ZA201503143B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
JO3470B1 (ar) *	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
WO2015036563A1 (de)	2013-09-16	2015-03-19	Bayer Pharma Aktiengesellschaft	Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten
PL3125894T3 (pl) *	2014-04-01	2021-02-08	Merck Sharp & Dohme Corp.	Proleki inhibitorów odwrotnej transkryptazy hiv
AU2015308350B2 (en)	2014-08-29	2020-03-05	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
FR3027901B1 (fr) *	2014-10-31	2018-03-16	Universite De Reims Champagne Ardenne	Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) *	2014-12-12	2019-07-16	Ojai Energetics Pbc	Methods and systems for forming stable droplets
US20190225955A1 (en)	2015-10-23	2019-07-25	President And Fellows Of Harvard College	Evolved cas9 proteins for gene editing
WO2018027078A1 (en)	2016-08-03	2018-02-08	President And Fellows Of Harard College	Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en)	2016-08-09	2023-11-09	President And Fellows Of Harvard College	Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en)	2016-08-24	2023-01-03	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko)	2016-10-14	2024-01-16	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	핵염기 에디터의 aav 전달
WO2018119359A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en)	2017-03-09	2020-01-15	President and Fellows of Harvard College	Suppression of pain by gene editing
WO2018165629A1 (en)	2017-03-10	2018-09-13	President And Fellows Of Harvard College	Cytosine to guanine base editor
IL269458B2 (en)	2017-03-23	2024-02-01	Harvard College	Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018209320A1 (en)	2017-05-12	2018-11-15	President And Fellows Of Harvard College	Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11732274B2 (en)	2017-07-28	2023-08-22	President And Fellows Of Harvard College	Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en)	2017-08-30	2022-05-03	President And Fellows Of Harvard College	High efficiency base editors comprising Gam
CA3075727A1 (en) *	2017-09-18	2019-03-21	Goldfinch Bio, Inc.	Pyridazinones and methods of use thereof
EP3697906A1 (en)	2017-10-16	2020-08-26	The Broad Institute, Inc.	Uses of adenosine base editors
WO2019157087A1 (en)	2018-02-06	2019-08-15	The General Hospital Corporation	Repeat rna as biomarkers of tumor immune response
TW202344505A (zh)	2018-04-30	2023-11-16	美商律幫治療股份有限公司	作為parp7抑制劑的嗒𠯤酮
MX2021003152A (es)	2018-09-18	2021-06-23	Goldfinch Bio Inc	Piridazinonas y sus metodos de uso.
KR102645602B1 (ko) *	2018-12-18	2024-03-07	머크 샤프 앤드 돔 엘엘씨	Hiv 감염된 세포에 대한 선택적 세포독성제로서의 피리미돈 유도체
MX2021011426A (es)	2019-03-19	2022-03-11	Broad Inst Inc	Metodos y composiciones para editar secuencias de nucleótidos.
CA3141143A1 (en)	2019-05-22	2020-11-26	Merck Sharp & Dohme Corp.	Pyridinone derivatives as selective cytotoxic agents against hiv infected cells
WO2021067946A1 (en) *	2019-10-04	2021-04-08	Goldfinch Bio, Inc.	Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
EP4051384A1 (en)	2019-10-30	2022-09-07	Ribon Therapeutics Inc.	Pyridazinones as parp7 inhibitors
US20230059640A1 (en)	2019-11-28	2023-02-23	Shionogi & Co., Ltd.	Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
TW202146416A (zh)	2019-12-11	2021-12-16	德商拜耳廠股份有限公司	吡唑并三𠯤
JP2023525304A (ja)	2020-05-08	2023-06-15	ザブロードインスティテュート，インコーポレーテッド	標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
CA3193099A1 (en)	2020-09-24	2022-03-31	David R. Liu	Prime editing guide rnas, compositions thereof, and methods of using the same
AU2022206476A1 (en)	2021-01-11	2023-07-20	President And Fellows Of Harvard College	Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
CA3220881A1 (en) *	2021-07-01	2023-01-05	Daniel Oehlrich	5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
AU2022325166A1 (en)	2021-08-06	2024-02-08	President And Fellows Of Harvard College	Improved prime editors and methods of use
WO2023076898A1 (en)	2021-10-25	2023-05-04	The Broad Institute, Inc.	Methods and compositions for editing a genome with prime editing and a recombinase
WO2023102538A1 (en)	2021-12-03	2023-06-08	The Broad Institute, Inc.	Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en)	2022-04-20	2023-10-26	The Broad Institute, Inc.	Improved prime editing methods and compositions
WO2023240137A1 (en)	2022-06-08	2023-12-14	The Board Institute, Inc.	Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en)	2022-10-07	2024-04-11	The Broad Institute, Inc.	Prime editing methods and compositions for treating triplet repeat disorders
WO2024108092A1 (en)	2022-11-17	2024-05-23	The Broad Institute, Inc.	Prime editor delivery by aav

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5665720A (en)	1992-08-07	1997-09-09	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
TR200003113T2 (tr)	1998-04-27	2001-05-21	Centre National De La Recherche Scientifique	3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması.
IT1305313B1 (it)	1998-07-17	2001-05-04	Colla Paolo	3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
AU2001291013A1 (en)	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
BRPI0407329A (pt)	2003-02-07	2006-01-10	Janssen Pharmaceutica Nv	Derivados de pirimidina para a prevenção de infecção de hiv
TW200423930A (en)	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en)	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
BRPI0408704A (pt)	2003-03-24	2006-03-07	Hoffmann La Roche	benzil-piridazinonas como inibidores de transcriptase reversa
WO2005070901A2 (en)	2004-01-12	2005-08-04	Gilead Sciences, Inc.	Pyrimidyl phosphonate antiviral compounds and methods of use
WO2005090317A1 (en)	2004-03-23	2005-09-29	F.Hoffmann-La Roche Ag	Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
SG152263A1 (en)	2004-04-23	2009-05-29	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja)	2004-12-22	2008-07-17	ファイザー・リミテッド	Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
BRPI0617720A2 (pt)	2005-10-19	2011-08-02	Hoffmann La Roche	compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
EP1940782B1 (en)	2005-10-19	2009-03-11	F.Hoffmann-La Roche Ag	N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
AU2007322608A1 (en)	2006-11-24	2008-05-29	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound and use thereof
US7803940B2 (en)	2006-11-24	2010-09-28	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
JP5539216B2 (ja) *	2007-11-20	2014-07-02	メルク・シャープ・アンド・ドーム・コーポレーション	非ヌクレオシド系逆転写酵素阻害剤
CA2710987A1 (en) *	2008-01-08	2009-07-16	Merck Sharp & Dohme Corp.	Process for preparing n-substituted hydroxypyrimidinone carboxamides
GEP20156368B (en) *	2010-03-30	2015-09-25	Merck Canada Inc	Non-nucleoside reverse transcriptase inhibitors
WO2011126969A1 (en)	2010-04-08	2011-10-13	Merck Sharp & Dohme Corp.	Prodrugs of an hiv reverse transcriptase inhibitor
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
PL3125894T3 (pl)	2014-04-01	2021-02-08	Merck Sharp & Dohme Corp.	Proleki inhibitorów odwrotnej transkryptazy hiv

2013
- 2013-09-29 JO JOP/2013/0284A patent/JO3470B1/ar active
- 2013-10-02 AR ARP130103568A patent/AR092876A1/es active IP Right Grant
- 2013-10-07 KR KR1020157011661A patent/KR101696128B1/ko active IP Right Grant
- 2013-10-07 PT PT171913072T patent/PT3295942T/pt unknown
- 2013-10-07 PT PT137767026T patent/PT2903977T/pt unknown
- 2013-10-07 HU HUE13776702A patent/HUE037231T2/hu unknown
- 2013-10-07 NZ NZ706729A patent/NZ706729A/en unknown
- 2013-10-07 DK DK19210167.3T patent/DK3656384T3/da active
- 2013-10-07 PL PL13776702T patent/PL2903977T3/pl unknown
- 2013-10-07 MY MYPI2015000836A patent/MY192716A/en unknown
- 2013-10-07 PT PT192101673T patent/PT3656384T/pt unknown
- 2013-10-07 US US14/047,515 patent/US9469634B2/en active Active
- 2013-10-07 PE PE2015001782A patent/PE20151787A1/es active IP Right Grant
- 2013-10-07 DK DK17191307.2T patent/DK3295942T3/da active
- 2013-10-07 TW TW105108710A patent/TWI598343B/zh active
- 2013-10-07 WO PCT/US2013/063612 patent/WO2014058747A1/en active Application Filing
- 2013-10-07 EP EP17191307.2A patent/EP3295942B1/en active Active
- 2013-10-07 AU AU2013329552A patent/AU2013329552B8/en active Active
- 2013-10-07 NO NO13776702A patent/NO2903977T3/no unknown
- 2013-10-07 MX MX2015004448A patent/MX355040B/es active IP Right Grant
- 2013-10-07 CA CA2887312A patent/CA2887312C/en active Active
- 2013-10-07 EA EA201590674A patent/EA033436B1/ru not_active IP Right Cessation
- 2013-10-07 LT LTEP19210167.3T patent/LT3656384T/lt unknown
- 2013-10-07 RS RS20220359A patent/RS63112B1/sr unknown
- 2013-10-07 JP JP2015535852A patent/JP5877281B2/ja active Active
- 2013-10-07 MD MD20150047A patent/MD4625C1/ro active IP Right Grant
- 2013-10-07 SI SI201331974T patent/SI3656384T1/sl unknown
- 2013-10-07 CN CN201380061513.7A patent/CN104822670B/zh active Active
- 2013-10-07 GE GEAP201313818A patent/GEP20186838B/en unknown
- 2013-10-07 ES ES17191307T patent/ES2770774T3/es active Active
- 2013-10-07 HU HUE19210167A patent/HUE058903T2/hu unknown
- 2013-10-07 EP EP13776702.6A patent/EP2903977B1/en active Active
- 2013-10-07 SI SI201331662T patent/SI3295942T1/sl unknown
- 2013-10-07 HR HRP20220502TT patent/HRP20220502T1/hr unknown
- 2013-10-07 PL PL17191307T patent/PL3295942T3/pl unknown
- 2013-10-07 LT LTEP13776702.6T patent/LT2903977T/lt unknown
- 2013-10-07 EP EP19210167.3A patent/EP3656384B1/en active Active
- 2013-10-07 SI SI201330835T patent/SI2903977T1/sl unknown
- 2013-10-07 UA UAA201504486A patent/UA114006C2/uk unknown
- 2013-10-07 LT LTEP17191307.2T patent/LT3295942T/lt unknown
- 2013-10-07 BR BR112015007742A patent/BR112015007742B8/pt active IP Right Grant
- 2013-10-07 DK DK13776702.6T patent/DK2903977T3/da active
- 2013-10-07 ES ES19210167T patent/ES2909190T3/es active Active
- 2013-10-07 ME MEP-2017-264A patent/ME02918B/me unknown
- 2013-10-07 HU HUE17191307A patent/HUE048670T2/hu unknown
- 2013-10-07 SG SG11201502620UA patent/SG11201502620UA/en unknown
- 2013-10-07 AP AP2015008355A patent/AP2015008355A0/xx unknown
- 2013-10-07 PL PL19210167T patent/PL3656384T3/pl unknown
- 2013-10-07 ES ES13776702.6T patent/ES2645638T3/es active Active
- 2013-10-07 RS RS20171164A patent/RS56543B1/sr unknown
- 2013-10-07 MA MA37959A patent/MA37959A2/fr unknown
- 2013-10-07 RS RS20200052A patent/RS59863B1/sr unknown
- 2013-10-07 TW TW102136225A patent/TWI538907B/zh active
2015
- 2015-03-23 TN TNP2015000106A patent/TN2015000106A1/fr unknown
- 2015-04-01 IL IL238090A patent/IL238090B/en active IP Right Grant
- 2015-04-06 PH PH12015500764A patent/PH12015500764A1/en unknown
- 2015-04-07 NI NI201500048A patent/NI201500048A/es unknown
- 2015-04-08 DO DO2015000082A patent/DOP2015000082A/es unknown
- 2015-04-08 CR CR20150183A patent/CR20150183A/es unknown
- 2015-04-08 GT GT201500088A patent/GT201500088A/es unknown
- 2015-04-08 CL CL2015000880A patent/CL2015000880A1/es unknown
- 2015-04-08 CO CO15077967A patent/CO7350655A2/es unknown
- 2015-05-07 ZA ZA2015/03143A patent/ZA201503143B/en unknown
- 2015-05-12 EC ECIEPI201518618A patent/ECSP15018618A/es unknown
- 2015-08-18 HK HK15107948.1A patent/HK1207369A1/xx unknown
2016
- 2016-01-25 JP JP2016011415A patent/JP6097422B2/ja active Active
- 2016-02-01 US US15/012,445 patent/US9718819B2/en active Active
2017
- 2017-06-07 US US15/616,756 patent/US10189831B2/en active Active
- 2017-11-20 CY CY20171101214T patent/CY1119655T1/el unknown
- 2017-11-22 HR HRP20171819TT patent/HRP20171819T1/hr unknown
2018
- 2018-09-20 HK HK18112148.6A patent/HK1252786A1/zh unknown
2020
- 2020-01-30 HR HRP20200158TT patent/HRP20200158T1/hr unknown
- 2020-02-04 CY CY20201100097T patent/CY1122585T1/el unknown
2022
- 2022-03-30 CY CY20221100247T patent/CY1125202T1/el unknown

Also Published As

Publication number	Publication date
US10189831B2 (en)	2019-01-29
DK2903977T3 (da)	2017-12-04
US9718819B2 (en)	2017-08-01
EP2903977A1 (en)	2015-08-12
PT2903977T (pt)	2017-11-14
HRP20220502T1 (hr)	2022-05-27
PL2903977T3 (pl)	2018-01-31
GEP20186838B (en)	2018-04-10
NZ706729A (en)	2018-09-28
AU2013329552C1 (en)	2016-12-22
ME02918B (me)	2018-10-20
MX2015004448A (es)	2016-02-17
MX355040B (es)	2018-03-28
HUE058903T2 (hu)	2022-09-28
LT2903977T (lt)	2017-12-11
US20160145255A1 (en)	2016-05-26
JP5877281B2 (ja)	2016-03-02
ES2770774T3 (es)	2020-07-03
BR112015007742B1 (pt)	2021-01-19
CL2015000880A1 (es)	2015-08-28
TW201623256A (zh)	2016-07-01
LT3295942T (lt)	2020-02-10
NI201500048A (es)	2016-06-29
ES2909190T3 (es)	2022-05-05
EA033436B1 (ru)	2019-10-31
EP3656384A1 (en)	2020-05-27
HK1252786A1 (zh)	2019-05-31
CR20150183A (es)	2015-08-10
JP6097422B2 (ja)	2017-03-15
PT3295942T (pt)	2020-02-18
GT201500088A (es)	2017-09-28
PL3656384T3 (pl)	2022-04-04
SG11201502620UA (en)	2015-05-28
PH12015500764B1 (en)	2015-07-27
EP3656384B1 (en)	2022-02-23
US20140100231A1 (en)	2014-04-10
HUE048670T2 (hu)	2020-08-28
TWI538907B (zh)	2016-06-21
EP3295942B1 (en)	2019-11-20
EP2903977B1 (en)	2017-09-20
HUE037231T2 (hu)	2018-08-28
AU2013329552A1 (en)	2015-04-16
AU2013329552B8 (en)	2017-01-12
US9469634B2 (en)	2016-10-18
EP3295942A1 (en)	2018-03-21
AU2013329552B2 (en)	2016-09-15
CA2887312C (en)	2017-02-28
EA201590674A1 (ru)	2016-02-29
CY1125202T1 (el)	2024-02-16
CY1119655T1 (el)	2018-04-04
LT3656384T (lt)	2022-05-10
CN104822670A (zh)	2015-08-05
BR112015007742A2 (pt)	2017-08-08
HK1207369A1 (en)	2016-01-29
WO2014058747A1 (en)	2014-04-17
CA2887312A1 (en)	2014-04-17
US20170349585A1 (en)	2017-12-07
KR101696128B1 (ko)	2017-01-13
PL3295942T3 (pl)	2020-05-18
ZA201503143B (en)	2016-06-29
RS63112B1 (sr)	2022-05-31
CO7350655A2 (es)	2015-08-10
IL238090B (en)	2019-02-28
MD4625B1 (ro)	2019-04-30
ES2645638T3 (es)	2017-12-07
MA37959A2 (fr)	2017-12-29
PT3656384T (pt)	2022-03-22
NO2903977T3 (da)	2018-02-17
DOP2015000082A (es)	2015-08-16
CY1122585T1 (el)	2021-01-27
MD4625C1 (ro)	2019-11-30
HRP20171819T1 (hr)	2017-12-29
JP2016128470A (ja)	2016-07-14
JP2015533123A (ja)	2015-11-19
SI3295942T1 (sl)	2020-03-31
AP2015008355A0 (en)	2015-04-30
KR20150065186A (ko)	2015-06-12
RS59863B1 (sr)	2020-03-31
MY192716A (en)	2022-09-05
JO3470B1 (ar)	2020-07-05
UA114006C2 (xx)	2017-04-10
SI3656384T1 (sl)	2022-05-31
MD20150047A2 (ro)	2015-08-31
CN104822670B (zh)	2018-01-12
RS56543B1 (sr)	2018-02-28
TWI598343B (zh)	2017-09-11
HRP20200158T1 (hr)	2020-08-07
SI2903977T1 (sl)	2017-12-29
TW201420576A (zh)	2014-06-01
AR092876A1 (es)	2015-05-06
PE20151787A1 (es)	2015-12-03
ECSP15018618A (es)	2019-06-30
DK3656384T3 (da)	2022-04-19
BR112015007742B8 (pt)	2021-03-23
TN2015000106A1 (en)	2016-06-29
PH12015500764A1 (en)	2015-07-27

Publication	Publication Date	Title
DK3295942T3 (da)	2020-02-10	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK3317286T3 (da)	2019-12-02	Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
DK3043865T3 (da)	2021-02-01	Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
DK2903600T3 (da)	2022-09-26	Virusholdig formulering og anvendelse deraf
DK3121164T3 (da)	2020-05-11	Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
DK2882496T3 (da)	2019-11-11	Behandling og diagnosticering af melanom
DK3494972T3 (da)	2024-01-29	Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
DK3608325T3 (da)	2022-08-22	Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK2903967T6 (da)	2020-07-13	Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme
DK2900657T3 (da)	2020-05-04	Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK2892912T3 (da)	2019-06-24	C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2838900T3 (da)	2019-10-14	Forbindelser og fremgangsmåder til antiviral behandling
DK3252160T3 (da)	2021-02-01	Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2958588T3 (da)	2017-11-20	Kombination af vaccination og hæmning af PD-1-reaktionsvejen
DK2818481T3 (da)	2019-10-14	Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2688557T3 (da)	2017-11-27	Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2882441T3 (da)	2020-05-25	Behandling af immunrelaterede og inflammatoriske sygdomme
DK3238707T3 (da)	2021-03-22	Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK2839004T3 (da)	2019-07-01	Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation
DK2917181T3 (da)	2020-01-13	Heteroarylderivater og anvendelser deraf
DK3366307T3 (da)	2021-11-01	Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2854910T3 (da)	2020-05-04	Ceramidniveauer i behandling og forebyggelse af infektioner
DK2809669T3 (da)	2017-05-01	Kondenserede pyrroldicarboxamider og deres anvendelse som farmaceutika
DK2800575T3 (da)	2019-07-01	Behandling af subarachnoidalblødning og iskæmi
DK3292873T3 (da)	2019-06-03	Kombination af vaccination og hæmning af PD-1-vejen